CBLI Earns "Buy" RatingCBLI Earns “Buy” Rating from WBB Securities, LLC
Regarding Cleveland BioLabs's radiation protection platform, the analyst observed that the Company's commercial opportunities fall into two primary categories.
The first is the HHS (Department of Health and Human Services) and BARDA (Biomedical Advanced Research and Development Authority) category, which deals with unintended radiation exposure. He stated that the Company has a unique opportunity to address radiation exposure, since there are not currently any existing products available that offer meaningful solutions.
In addition, the analyst noted the Company's potential for traditional medical indications for the same technology.